Severe SARS-Cov2 pneumonia in vaccinated patients: a multicenter cohort study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 02 2023
02 02 2023
Historique:
received:
04
04
2022
accepted:
31
01
2023
entrez:
2
2
2023
pubmed:
3
2
2023
medline:
7
2
2023
Statut:
epublish
Résumé
Vaccination reduces risk of infection, hospitalization, and death due to SARS-Cov2. Vaccinated patients may however experience severe SARS-Cov2 disease. The objective was to describe clinical features of vaccinated patients requiring intensive care unit (ICU) admission due to SARS-Cov2 infection and compare them to a published cohort of unvaccinated patients. We performed a multicenter cohort study of patients with severe SARS-Cov2 disease admitted to 15 ICUs in France between January and September 2021. 100 consecutive vaccinated patients (68 (68%) men, median age 64 [57-71]) were included. Immunosuppression was reported in 38 (38%) patients. Among available serologies at ICU admission, 64% exhibited an optimal antibody level. Median SOFA score at ICU admission was 4 [4-6.3] and median PaO2/FiO2 ratio was 84 [69-128] mmHg. A total of 79 (79%) and 18 (18%) patients received high flow nasal oxygen and non-invasive mechanical ventilation, respectively. Invasive mechanical ventilation (IMV) was initiated in 48 (48%) with a median duration of 11 [5-19] days. During a median ICU length-of-stay of 8 [4-20] days, 31 (31%) patients died. Age (OR per 5-years increment 1.38 CI95% [1.02-1.85], p = 0.035), and SOFA at ICU admission (OR 1.40 CI95% [1.14-1.72] per point, p = 0.002) were independently associated with mortality. When compared to a cohort of 1316 unvaccinated patients (72% men, median age 63 [53-71]), vaccinated patients exhibited less frequently diabetes (16 [16%] vs. 351 [27%], p = 0.029) but were more frequently immunosuppressed (38 [38%] vs. 109 (8.3%), p < 0.0001), had more frequently chronic kidney disease (24 [24%] vs. 89 (6.8%), p < 0.0001), chronic heart failure (16 [16%] vs. 58 [4.4%], p < 0.0001), and chronic liver disease (3 [3%] vs. 8 [0.6%], p = 0.037) compared to unvaccinated patients. Despite similar severity, vaccinated patients required less frequently IMV at ICU day 1 and during ICU stay (23 [23%] vs. 785 [59.7%], p < 0.0001, and 48 [48%] vs. 930 [70.7%], p < 0.0001, respectively). There was no difference concerning ICU mortality (31 [31%] vs. 379 [28.8%], p = 0.64). Severe SARS-Cov2 infection after vaccination occurs mainly in patients with immunosuppression, chronic kidney, heart or liver failure. Age and disease severity are independently associated with mortality.
Identifiants
pubmed: 36732353
doi: 10.1038/s41598-023-29131-9
pii: 10.1038/s41598-023-29131-9
pmc: PMC9893202
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1902Informations de copyright
© 2023. The Author(s).
Références
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131
pubmed: 35085222
Ann Intern Med. 2022 Mar;175(3):352-361
pubmed: 34928700
Ann Rheum Dis. 2021 Oct;80(10):1322-1329
pubmed: 34362747
Cell. 2022 Mar 17;185(6):1008-1024.e15
pubmed: 35202565
Nat Med. 2021 Jul;27(7):1147-1148
pubmed: 34239135
JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
Lancet Respir Med. 2021 Dec;9(12):1439-1449
pubmed: 34599903
Cell. 2021 Mar 4;184(5):1201-1213.e14
pubmed: 33571429
Clin Infect Dis. 2022 Aug 24;75(1):e849-e856
pubmed: 34893812
Lancet Microbe. 2022 Feb;3(2):e81-e82
pubmed: 34901897
Intensive Care Med. 2022 Mar;48(3):362-365
pubmed: 35050384
Cell. 2022 Jan 6;185(1):113-130.e15
pubmed: 34921774
J Pers Med. 2021 Oct 25;11(11):
pubmed: 34834437
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Sci Immunol. 2022 Mar 25;7(69):eabo2202
pubmed: 35113647
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Ann Rheum Dis. 2022 Mar;81(3):422-432
pubmed: 34876462
Ann Rheum Dis. 2022 Feb;81(2):289-291
pubmed: 34489304
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Intern Med J. 2022 Jul 16;:
pubmed: 35841294
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
Lancet Reg Health Eur. 2021 Dec;11:100243
pubmed: 34751263
Cell. 2022 Feb 17;185(4):603-613.e15
pubmed: 35026152
BMJ. 2021 Sep 17;374:n2244
pubmed: 34535466